Loading…

Bayer AGBAYN.DECompetitor analysis, valuation and peers

Germany · EUR·Health Care›Pharmaceuticals: Major

German pharmaceutical and agriculture company selling prescription drugs, consumer health products, and crop seeds/pesticides (via Monsanto).

≈ Germany's Pfizer, combined with Monsanto's crop science businessMomentum leader 99
Mkt cap
$60.3B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$166M
20-day average traded
Fwd P/E
12.3×
forward earnings
ROIC−WACC
+0.2 pp
WACC 5.6%
Hurdle
n/a
no reverse DCF
Official | Implied
BBB / A-
agencies · bond market
Next earnings
98 days
24 Feb 2027
Close · EUR€55.94
1D-0.4%
1W-1.4%
1M+28.7%
3M+16.4%
6M+47.9%
YTD+51.1%
1Y+107.0%
ATR %2.7%
52w lowhigh3.3% off high

What Bayer does

German pharmaceutical and agriculture company selling prescription drugs, consumer health products, and crop seeds/pesticides (via Monsanto).

Sells prescription drugs, crop seeds and crop chemicals, and over-the-counter health products, with Crop Science the largest division by sales since the 2018 purchase of Monsanto. Bayer's own sales of its two biggest drugs come from outside the US, where partners J&J (Xarelto) and Regeneron (Eylea) sell them.

In one line: Germany's Pfizer, combined with Monsanto's crop science business.

Products and services

  • Pharmaceuticals (Xarelto, Eylea)
  • Crop Science (seeds, Roundup/glyphosate)
  • Consumer Health (Aspirin, Claritin)

Customers

  • Hospitals & physicians
  • Farmers
  • Retail consumers (OTC)

Where it sits in the supply chain

  • Pharma & agriculture
  • Drug R&D + agricultural biotech
  • Prescription pharma, consumer health…

What could go right

  • Crop science demand/seed technology adoption
  • New drug pipeline launches
  • Litigation settlement resolution

What could go wrong

  • Roundup/glyphosate litigation liability
  • Patent expirations (Xarelto, Eylea)
  • Agricultural commodity price cycles

Moat: narrow (IP / patents, scale, brand). Patented drugs and leading crop-seed genetics, though facing major glyphosate litigation and patent cliffs.

Headquarters: Leverkusen, Germany · Founded: 1863 · Employees: 88,078

Named competitors

Bayer at a glance

Size Bayer (BAYN.DE) is a Germany Health Care company (Pharmaceuticals: Major) with a market value of $60.3B, the 11th largest of 198 Germany companies the cockpit tracks. Shares closed at €55.94 on 18 Nov 2026.

Performance Over six months the shares gained 47.9%, against +14.7% for the median peer and -0.9% for the Germany market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue fell 0.2% over the last twelve months (peer median +11.7%); the operating margin is 12.6% (peer median 23.3%).

Valuation It trades at 12.3× forward earnings against a peer median of 17.9× (5th cheapest of 21).

Capital Return on invested capital runs 0.2 points above its cost of capital (5.6% WACC).

Credit Bayer has 36 bonds outstanding ($38.4B), rated BBB by the agencies and trading like A- at a weighted spread of 110 bp.

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026BAYN.DE 147Peer median 115
Six months, rebased to 100: Bayer against the median of its 20 peers (local-currency closes).

Bayer financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€45.8B€45.6B€46.6B€47.6B€50.7B
Revenue growth—-2%-2%-6%—
Gross profit€26.9B€27.0B€25.3B€27.9B€30.9B
EBITDA€10.0B€11.0B€8.53B€12.3B€12.2B
Net income-€1.45B-€3.62B-€2.55B-€2.94B€4.15B
Free cash flow-€93.0M€2.08B€3.11B€1.31B€3.11B
Capital expenditure€2.59B€2.49B€2.78B€2.75B€2.95B
Total debt€43.4B€37.4B€40.7B€44.8B€41.5B

Quarterly statements and history in the cockpit →

Bayer competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%+20%23594502GALDMRK4519SUNPHARMA600276688235SDZ4578HLNRPRXREGNBIIBGSKZTSSAN45034568DIVISLABBAYN.DE6-month return →1-month return →
Up and to the right = strong over both horizons. Bayer is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×60×23594502GALDMRK4519SUNPHARMA600276688235SDZ4578HLNRPRXREGNGSKZTSSAN45034568DIVISLABBAYN.DERevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bayer is the large dot.

Bayer competitors and peer comparison

Head to head with its named competitors (BAYN.DE vs CTVA vs PFE vs BAS.DE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Bayer BAYN.DE$60.3B+48%0%13%12.3×n/a
Corteva CTVA$5.58B-89%+1%16%15.6×n/a
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Basf BAS.DE$50.1B0%-4%7%15.8×5.7%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%

How Bayer compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bayer against its 20 peers (data as of 18 Nov 2026)
MeasureBAYN.DEPeer medianRank in peer set
1-month return+28.7%+6.3%highest of 21
6-month return+47.9%+14.7%3rd highest of 21
Distance from 52-week high-3.3%-6.4%5th highest of 21
Revenue growth (TTM)-0.2%+11.7%lowest of 21
Operating margin12.6%23.3%2nd lowest of 21
Forward P/E12.3×17.9×5th cheapest of 21
ROIC minus cost of capital+0.2 pp+5.4 pp3rd lowest of 21
EV / EBITDA9.2×13.8×4th cheapest of 19
Net debt / EBITDA3.4×1.1×2nd most indebted of 19
Bond spread110 bp84 bpwidest of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
Wuxi Apptec 2359.HKHong Kong$64.1B+51%+38%44%19.5×8.4%+20.4%
Takeda Pharmaceutical 4502.TJapan$69.8B+30%+6%18%51.0×3.7%+7.1%
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Merck KGaA MRK.DEGermany$71.3B+16%+1%19%17.4×7.4%+3.8%
Chugai Pharmaceutical 4519.TJapan$75.2B-8%+17%50%23.7×5.0%+9.8%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
Jiangsu Hengrui Pharmaceuticals 600276.SSChina$45.7B-13%+6%27%33.4×13.4%+2.7%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%11.5×10.8%+2.3%
Regeneron Pharmaceuticals REGNUnited States$97.8B+46%+19%30%11.8×-1.1%+11.0%
Biogen BIIBUnited States$37.2B+34%+2%17%17.1×10.1%-5.1%
GSK GSK.LUnited Kingdom$97.9B-3%+4%25%10.4×-0.1%-0.9%
Zoetis ZTSUnited States$34.8B+7%+1%37%13.8×-2.9%+7.2%
Sanofi SAN.PAFrance$114B+13%+15%27%9.7×-4.8%+3.9%
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%12.9×-9.0%+11.4%
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%18.4×7.6%+17.1%
Divi's Laboratories DIVISLAB.NSIndia$31.3B+60%+22%34%73.5×47.1%+8.9%

Bayer bonds and credit

Bayer has 36 bonds outstanding with $38.4B face value. The agencies rate it BBB; its bonds trade like A-. Weighted yield 5.34%, a spread of 110 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Bayer's main competitors?
Named competitors: Corteva Inc (CTVA), Syngenta (ChemChina, private) (private or unlisted), Pfizer (PFE), BASF (crop protection) (BAS.DE), Novartis (NOVN.SW). The cockpit's measured peer set (industry) also includes Wuxi Apptec (2359.HK), Takeda Pharmaceutical (4502.T), Galderma (GALD.SW), Merck KGaA (MRK.DE), Chugai Pharmaceutical (4519.T), Sun Pharmaceutical Industries (SUNPHARMA.NS).
Is Bayer expensive compared with its peers?
On forward p/e it trades at 12.3× against a peer median of 17.9×, 5th cheapest of 21 in its peer set.
How has Bayer stock performed?
Over six months to 18 Nov 2026 the shares returned +47.9% against +14.7% for the median peer; over one year +107.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.